USANA Health Sciences (NYSE:USNA – Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, July 22nd. Analysts expect the company to announce earnings of $0.54 per share and revenue of $225.20 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS.
USANA Health Sciences (NYSE:USNA – Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.70 by $0.03. The business had revenue of $249.54 million during the quarter, compared to analysts’ expectations of $243.08 million. USANA Health Sciences had a return on equity of 8.94% and a net margin of 3.98%. During the same period in the prior year, the firm posted $0.86 EPS. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
USANA Health Sciences Trading Down 1.5%
Shares of USNA stock opened at $32.51 on Tuesday. The company has a market cap of $605.35 million, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 1.05 and a beta of 0.64. The stock has a 50 day simple moving average of $30.41 and a 200-day simple moving average of $30.28. USANA Health Sciences has a 12-month low of $23.10 and a 12-month high of $48.85.
Insiders Place Their Bets
Institutional Trading of USANA Health Sciences
An institutional investor recently bought a new position in USANA Health Sciences stock. Empowered Funds LLC acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNA – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,483 shares of the company’s stock, valued at approximately $687,000. Empowered Funds LLC owned about 0.14% of USANA Health Sciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 54.25% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd.
Check Out Our Latest Stock Analysis on USNA
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Read More
- Five stocks we like better than USANA Health Sciences
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- These 3 Undervalued Stocks Could Surge as Value Rotation Nears
- Best Energy Stocks – Energy Stocks to Buy Now
- Tilray Shares Blazing: What’s Behind the 55% Rally This Month?
- How to Profit From Growth Investing
- 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.